Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B.1.1.7 and SA B.1.351 variant
A. Weiss, F. Touret, C. Baronti, M. Gilles, B. Hoen, A. Nougairede, X. de Lamballerie, M. O. A. Sommer
Abstract
SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide is effective against the D614G, B.1.1.7 and B.1.351 variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment.
J. W. Wotring, S. M. McCarty, … J. Z. Sexton·bioRxiv·Jun 24, 2022
- Broad-spectrum, patient-adaptable inhaled niclosamide-lysozyme particles are efficacious against coronaviruses in lethal murine infection models
A. D. Brunaugh, H. Seo, … H. D. C. Smyth·bioRxiv·Sep 24, 2020
- Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant
A.-K. Reuschl, L. Thorne, … N. J. Krogan·bioRxiv·Jan 24, 2021
- Fast and scalable lipid nanoparticle formulation of niclosamide (nano NCM) effectively inhibits SARS-CoV-2 replication in vitro
G. Wang, H. Gaikwad, … D. Simberg·bioRxiv·Dec 18, 2020
- Methylene blue, Mycophenolic acid, Posaconazole, and Niclosamide inhibit SARS-CoV-2Omicron variant BA.1 infection of human airway epithelial explant cultures
R. Volle, L. Murer, … U. F. Greber·bioRxiv·Mar 30, 2022
- An intranasal ASO therapeutic targeting SARS-CoV-2
C. Zhu, J. Y. Lee, … A. M. Näär·bioRxiv·May 17, 2021